News Results

There are 644,321 News Results

Dec 1, 2020
Trip.com Group Reports Unaudited Third Quarter of 2020 Financial Results
SHANGHAI, Dec. 1, 2020 /PRNewswire/ -- Trip.com Group Limited (Nasdaq: TCOM) ("Trip.com Group" or the "Company"), a leading provider of online travel and related services, including accommodation reservation, transportation ticketing,...
Dec 2, 2020
Discovery Announces The Global Launch Of discovery+, The Definitive Streaming Service For The Best Real-Life Entertainment in The World, Debuting January 4, 2021
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Discovery, Inc. (Nasdaq: DISCA, DISCB, DISCK) today announced the global launch of discovery+ ( www.discoveryplus.com ), the definitive non-fiction, real-life subscription streaming service,...
Dec 3, 2020
Chevron Offers to Exchange Series of Notes Issued by Noble Energy, Inc.
Chevron Corporation (“Chevron”) (NYSE:CVX) and Chevron U.S.A. Inc. (“CUSA”) today announced the commencement of offers to exchange (the “exchange offers”) any and all validly tendered (and not validly withdrawn) and...
Dec 4, 2020
The Medical Opportunity Flying Under Wall Street's Radar
LONDON, Dec. 4, 2020 /PRNewswire/ -- Depression is now the number one disability in the world. And it's costing the economy
Dec 4, 2020
Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Regimen After First or Subsequent Relapse in Multiple Myeloma
RARITAN, N.J., Dec. 4, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of the Phase 3 APOLLO study showing that the addition of DARZALEX
Dec 8, 2020
Cantel Medical Reports Financial Results for its First Quarter Fiscal Year 2021
LITTLE FALLS, N.J., Dec. 8, 2020 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMD) today announced financial results for its first quarter ended October 31, 2020. First quarter 2021 net sales...
Dec 9, 2020
Upadacitinib (RINVOQ(TM)) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis
NORTH CHICAGO, Ill., Dec. 9, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from the Phase 3 induction study, U-ACHIEVE, which showed upadacitinib (45 mg, once daily) met...
Dec 9, 2020
Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®
INDIANAPOLIS, Dec. 9, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced additional data from a pre-planned primary outcome analysis from the Phase 3 monarchE trial that showed...
Dec 10, 2020
RINVOQ(TM) (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
NORTH CHICAGO, Ill., Dec. 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved...
Dec 11, 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
NORTH CHICAGO, Ill., Dec. 11, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval...
64433

Pages

1

Stories of the day

Sep 25, 2025
Boeing to Relocate F/A-18 Service Life Modification Work to Support St. Louis...
Sep 25, 2025
Integrated Battle Command System Achieves Major Milestone with First Successful...
Sep 25, 2025
RTXs Raytheon and Avio USA expand collaboration to accelerate Mk 104 rocket...
Sep 26, 2025
Latvia orders Rheinmetall ammunition factory – Group expands global ammunition...